A detailed history of Captrust Financial Advisors transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 12,307 shares of RNXT stock, worth $12,553. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,307
Holding current value
$12,553
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$0.77 - $1.42 $9,476 - $17,475
12,307 New
12,307 $16,000

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $9.25M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.